Aimmune Therapeutics Inc (NASDAQ:AIMT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

AIMT has been the subject of several other reports. Wedbush reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Friday, December 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Aimmune Therapeutics in a report on Monday, February 13th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Aimmune Therapeutics has a consensus rating of “Buy” and a consensus target price of $33.60.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/zacks-investment-research-downgrades-aimmune-therapeutics-inc-aimt-to-sell.html

Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.80% during trading on Monday, reaching $22.61. The company’s stock had a trading volume of 261,580 shares. The stock’s 50 day moving average is $20.11 and its 200 day moving average is $19.52. The company’s market cap is $958.26 million. Aimmune Therapeutics has a 12 month low of $9.77 and a 12 month high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, March 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.08. On average, equities analysts expect that Aimmune Therapeutics will post ($2.80) EPS for the current fiscal year.

Your IP Address:

Institutional investors have recently added to or reduced their stakes in the stock. TD Asset Management Inc. raised its position in Aimmune Therapeutics by 136.7% in the third quarter. TD Asset Management Inc. now owns 31,478 shares of the company’s stock valued at $472,000 after buying an additional 18,178 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Aimmune Therapeutics during the third quarter valued at approximately $579,000. Wells Fargo & Company MN increased its position in Aimmune Therapeutics by 6.7% in the third quarter. Wells Fargo & Company MN now owns 54,933 shares of the company’s stock valued at $824,000 after buying an additional 3,454 shares during the last quarter. Columbus Circle Investors purchased a new position in Aimmune Therapeutics during the third quarter valued at approximately $918,000. Finally, Norges Bank purchased a new position in Aimmune Therapeutics during the fourth quarter valued at approximately $1,258,000. 61.61% of the stock is owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.